Literature DB >> 20541274

Influence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancer.

Sonia K A Nguyen1, Laurence Masson-Côté, André Fortin, Anne Dagnault.   

Abstract

BACKGROUND AND
PURPOSE: The role of post-operative radiotherapy in patients with resected non-small-cell lung cancer (NSCLC) is unclear. Modifiable factors, like smoking, may help guide therapy. We retrospectively evaluated the impact of smoking on control in patients undergoing post-operative radiation therapy (PORT) for NSCLC.
MATERIALS AND METHODS: Between 1995 and 2007, 152 patients who underwent surgery for NSCLC were analyzed (median follow-up 26 months). Non-smokers were defined as patients who never smoked or who had stopped smoking at the time of initial consultation. Sixty seven percent were non-smokers; 5% never smoked, 40% of the non-smokers had ceased smoking for a year or less, while 55% had stopped for more than a year.
RESULTS: On univariate analysis, smokers had worse 5-year local control than non-smokers (70% versus 90%, p=0.001) and locoregional control (52% versus 77%, p=0.002). The 5-year survival rate was 21% for smokers and 31% for non-smokers (p=0.2). On multivariate analysis, smokers maintained a detrimental effect on locoregional control (HR 3.6, p=0.0006).
CONCLUSIONS: Smokers at initial consultation have poorer local and locoregional control after PORT than non-smokers. In patients being considered for PORT for NSCLC, quitting smoking before treatment confers additional treatment advantage. Crown Copyright 2010. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541274     DOI: 10.1016/j.radonc.2010.05.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Authors:  Raymond H Mak; Elizabeth Doran; Alona Muzikansky; Josephine Kang; Joel W Neal; Elizabeth H Baldini; Noah C Choi; Henning Willers; David M Jackman; Lecia V Sequist
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Post-operative radiation therapy.

Authors:  Amaury Paumier; Cécile Le Péchoux
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells.

Authors:  Mary Zhang; Aarti Mathur; Yuwei Zhang; Sichuan Xi; Scott Atay; Julie A Hong; Nicole Datrice; Trevor Upham; Clinton D Kemp; R Taylor Ripley; Gordon Wiegand; Itzak Avital; Patricia Fetsch; Haresh Mani; Daniel Zlott; Robert Robey; Susan E Bates; Xinmin Li; Mahadev Rao; David S Schrump
Journal:  Cancer Res       Date:  2012-07-02       Impact factor: 12.701

Review 4.  Tobacco use and cessation for cancer survivors: an overview for clinicians.

Authors:  Maher Karam-Hage; Paul M Cinciripini; Ellen R Gritz
Journal:  CA Cancer J Clin       Date:  2014-05-09       Impact factor: 508.702

5.  Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy.

Authors:  Zhouguang Hui; Honghai Dai; Jun Liang; Jima Lv; Zongmei Zhou; Qinfu Feng; Zefen Xiao; Dongfu Chen; Hongxing Zhang; Weibo Yin; Luhua Wang
Journal:  Thorac Cancer       Date:  2015-04-24       Impact factor: 3.500

6.  Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer.

Authors:  Xuquan Jing; Xue Meng; Xindong Sun; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

7.  Hypofractionated carbon-ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study.

Authors:  Jun-Ichi Saitoh; Katsuyuki Shirai; Tatsuji Mizukami; Takanori Abe; Takeshi Ebara; Tatsuya Ohno; Koichi Minato; Ryusei Saito; Masanobu Yamada; Takashi Nakano
Journal:  Cancer Med       Date:  2019-09-18       Impact factor: 4.452

8.  Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma.

Authors:  Cuimeng Tian; Guimei Liu; Yongxiang Xu; Guangrong Xia; Tongmei Zhang; Jiaqiang Huang; Hui Jiang; Ji Ming Wang; Baolan Li
Journal:  Radiol Oncol       Date:  2020-12-03       Impact factor: 2.991

Review 9.  Impact of Tobacco Smoking on Outcomes of Radiotherapy: A Narrative Review.

Authors:  Adrian Perdyan; Jacek Jassem
Journal:  Curr Oncol       Date:  2022-03-24       Impact factor: 3.109

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.